skip to main content



Strong pre-clinical data has been generated in a new solid tumour indication, glioma/glioblastoma with further pre-clinical work underway and designs for a Phase Ib/IIa trial being assessed.

Pre-clinical work has also commenced in a further cancer indication based on new evidence that SFX-01 inhibits the SHP2 pathway. Cancers where the SHP2 pathway is implicated are being assessed and a decision on the third area of investigation of SFX-01 in cancer will be made in the near future.

Evgen Pharma also supports a number of other investigator-led pre-clinical studies on SFX-01 in other therapeutic areas.